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brain and oral cavity. This has led to their widespread use in 
evidence-based patient management. Radiation oncologists in SA, as 
elsewhere, will seek to participate in clinical research based on these 
and other novel approaches.
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Neutron radiotherapy: Society 
comments
To the Editor: The radiation oncology community in South Africa 
can no longer support the continuation of neutron therapy. The 
lack of new phase III data to support this treatment modality and 
the fact that patients numbers never really materialised resulted in 
very inefficient utilisation of available resources that could have been 
better spent. Progress in clinical and radiation oncology during the 
past 20 years with new technologies readily available in this country 
resulted in even fewer reasons to continue this programme. The 
logistics involved in trying to utilise this as a national resource – 
which would be the same if one were to try and argue for this to be 
used as a resource for the continent of Africa – would result in even 
less benefit to society as a whole. 
South Africa can no longer afford to fund such programmes given 
the many competing priorities in oncology and health in general. To 
do so would border on being socially irresponsible. 
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Neutron radiotherapy: Abratt supported
To the Editor: We write, with some unease, given that much of this 
matter is internal to the medical affairs of South Africa (SA), to 
lend support to the stance of Prof Abratt,1,2 regarding closure of the 
neutron facility in SA.
We recognise clearly the limitations of participating in this debate 
when we are not South African and do not practise medicine in 
the African continent. That said, there are points of illogic in the 
criticisms of Prof Abratt’s stand that must be challenged.
Firstly, the rhetoric supporting the purported importance of 
recent research on neutron therapy, and the charge that Prof Abratt’s 
view of neutron therapy is outdated, are simply unreasonable. 
The whole issue of the utility of neutron therapy remains highly 
controversial internationally after more than 25 years of research 
and clinical practice. The issues remain unchanged: lack of proven 
benefit, narrow spectrum of clinical indications, offset by excessive 
toxicity demonstrated in the majority of published studies. While we 
recognise the difficulty of completing randomised clinical trials in 
this setting, it is important to note the absence of high-quality data to 
support this expensive technology.
Despite the claims of the proponents of such research on the topic 
of neutron therapy, we note a paucity of well-structured published 
research on the role of this treatment modality. It appears that the 
majority of use of available equipment has been for routine clinical 
practice, despite the absence of significant, recent published data to 
support such therapy; one might have hoped that investigational 
equipment might have been used to produce new data.
Perhaps of more importance, in a continent that is challenged by 
a shortage of costly medical resources, it seems importune to make 
a case for maintenance of an expensive, controversial, unproven 
therapy with so few indications, and to criticise an earnest and honest 
attempt to bring reason to the debate. We support Prof Abratt’s 
view, based on logic, fiscal pragmatism, and recognise his presence 
as a leader in academic radiation oncology with several decades of 
carefully structured published data.
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Traumatic rhabdomyolysis (crush 
syndrome) in the rural setting
To the Editor: I read with interest the article entitled ‘Traumatic 
rhabdomyolysis (crush syndrome) in the rural setting’.1 Crush syndrome 
from sjambok injury is a uniquely southern African experience.2 It is 
unfortunately commonplace, making treatment guidelines essential to 
prevent the progression of acute kidney injury (AKI) and subsequent 
need for renal replacement therapy. The advent of the RIFLE and 
AKIN criteria in the description and risk stratification of AKI provides 
a framework from which strategies to prevent ongoing injury can be 
implemented.3 Their use has become commonplace in critical care and 
should be implemented in the emergency department.
Careful monitoring of fluid balance is essential, and a paper 
discussing the ATN and RENAL trial results shows that avoiding 
a positive fluid balance improves renal recovery times.4 Therefore 
I urge caution in trying to force a diuresis with resuscitation fluids 
if patients present with anuria/oliguria and do not respond to 
initial fluid therapy as they can be pushed into fluid overload with 
subsequent need for ventilatory support.
Alkalinisation of the urine with bicarbonate has been challenged 
as the standard of care. Evidence for this practice is weak; in 
2 083 trauma ICU admissions, Velmahos’ group failed to show 
improvement in outcomes despite urinary alkalinisation.5
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The use of diuretics in AKI does not improve mortality outcomes and 
the use of renal replacement therapy.6 Mannitol has also been implicated as 
a cause of AKI in head-injured patients and should be used with caution.7
At present, measuring serum creatinine and urine output remain 
the two best indicators of renal function that are easily available to the 
clinician. These remain our renal biomarkers of choice until the use 
of newer renal biomarkers, such as neutrophil gelatinase associated 
lipocalin and cystatin C, becomes commonplace.8
Patient therapy must be individualised, with haemodynamic 
optimisation and careful monitoring of fluid balance, specifically 
concentrating on urine output. Care must be taken to avoid 
nephrotoxic agents such as intravenous contrast and aminoglycosides. 
Early referral for renal replacement therapy is essential in those not 
responding to conventional fluid therapy.
D L Skinner
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Wood replies: Traumatic rhabdomyolysis is often a result of natural 
disasters such as earthquakes where patients are crushed by debris. 
However, rhabdomyolysis associated with interpersonal violence 
such as sjambok injuries and community beatings is endemic 
to South Africa. Most of these patients present to district or 
regional hospitals with limited diagnostic capabilities and no renal 
replacement therapies such as renal dialysis. Our study1 suggests 
that early diagnosis of rhabdomyolysis using clinical examination 
and blood on urine Dipstix as a surrogate marker are critical in 
preventing ensuing myoglobin-associated acute renal failure. Key 
to management is early and aggressive fluid management (a target 
of 200 - 300 ml/h urine output)2 to prevent renal tubule damage. A 
low urine pH augments myoglobin cast sedimentation3 and renal 
tubular damage. Some guidelines2,3 suggest the use of bicarbonate, 
with a target urine pH >6.5, to reduce this effect. Caution is advised 
with bicarbonate therapy since hypocalcaemia, hypernatraemia, 
systemic alkalosis and potential tetany are potential adverse effects. 
Most guidelines also recommend the use of mannitol in oliguric 
patients.2,3 Theoretical advantages of mannitol include osmotic 
diuresis, free radical scavenging and stimulating the release of 
vasodilatory prostaglandins, enhancing glomerular filtration. The 
use of mannitol and bicarbonate is controversial, with new evidence 
suggesting that their use is of no benefit in rhabdomyolysis.
One study showed that bicarbonate and mannitol therapy had no 
advantage in preventing renal failure over saline diuresis alone.4 However, 
the study was not randomised and patients in the mannitol/bicarbonate 
group had an overall higher average creatine kinase, suggesting a more 
severe pathology. The study indicated that patients with a creatine kinase 
>30 000 U/l may benefit from mannitol/bicarbonate therapy.4,5 The use 
of mannitol and bicarbonate in this setting should be revisited.
In settings with limited or no renal support such as renal dialysis, 
preventing renal failure in traumatic rhabdomyolysis is critical. Early 
detection of rhabdomyolysis and fluid therapy is the cornerstone 
of renal saving. Patients who do not respond to fluid resuscitation 
and show an increasing trend toward renal failure as indicated by a 
climbing serum creatinine may need additional treatment strategies 
when dialysis services are not an option. They should have their 
intravascular volume monitored, which in most settings is limited 
to central venous pressure monitoring, before the use of diuretics 
such as mannitol is considered. Strict monitoring of urine and serum 
pH when considering the use of bicarbonate is recommended. Our 
small observational study in a rural regional hospital showed that 
patients with suspected rhabdomyolysis can be effectively treated 
using recommended guidelines where resources are not adequate for 
renal replacement treatments. Serious clinical dilemmas exist when 
patients don’t respond to fluid therapy alone and show worsening 
renal functions, and where there is no recourse to services such as 
renal dialysis.
Large prospective randomised controlled trials are required to 
provide clarity on the most effective treatment strategies in trauma-
associated rhabdomyolysis, especially in the resource-challenged 
areas to which most patients present.
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False-positive HIV DNA PCR testing 
of infants
To the Editor: I would like to share ideas on the report by Feucht et al. 
who concluded that ‘Decreasing mother-to-child HIV transmission 
rates reduce the positive predictive value of a single HIV DNA PCR 
test result, necessitating adaptations to diagnostic algorithms to 
avoid misdiagnosis and inappropriate treatment, especially with early 
initiation of antiretroviral therapy in asymptomatic infants.’1
False positivity is basic in laboratory medicine and can result from any 
tests, including molecular diagnoses. The basic concept to consider when 
discussing the diagnostic property of a test is that prevalence is the main 
factor determining sensitivity, specificity and predictive values, which 
can be reflected in their report. The authors’ conclusions are based on a 
single centre with retrospective data review, which cannot control for the 
confounding factors and quality of the laboratory test.
Despite the use of molecular testing for HIV diagnosis, practitioners 
must be concerned about the possibility of false positivity, as available 
commercial kits for HIV molecular testing differ in their false- 
positive rates.2 The information on the false-positive rate of each 
diagnostic test should be available for interpretation of the results. 
There should also be a focus on the quality of the diagnostic test, as 
poor quality of some locally available in-house HIV molecular testing 
owing to contamination has been reported.3
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